Bio Pharma Dive
JULY 18, 2024
The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.
Pharmaceutical Technology
JULY 18, 2024
Johnson & Johnson has reported a 12.8% decrease in net earnings for Q2 2024, with figures falling to $4.6bn from $5.3bn in Q2 2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 18, 2024
Home Editorial Services Interview Q&A Chronicle Specials Pharma Mart ePharmail Archives Join Pharma | Login Home > TopNews you can get e-magazine links on WhatsApp.
Bio Pharma Dive
JULY 18, 2024
The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 18, 2024
Patients taking Eli Lilly’s new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk’s Ozempic, a head-to-head study published Monday showed.
Pharmaceutical Technology
JULY 18, 2024
Ardelyx and two other organisations have filed a lawsuit, opposing the HHS' and CMS’ revamped kidney disease payment scheme.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JULY 18, 2024
Novartis has reported a 43% increase in net income from continuing operations reaching $3.24bn in the second quarter (Q2) of 2024.
Fierce Pharma
JULY 18, 2024
Pfizer’s blockbuster drug tafamidis for the treatment of the rare heart disease transthyretin amyloid cardiomyopathy (ATTR-CM) needs at least a 96% discount off its list price to be considered cost | Pfizer’s blockbuster tafamidis for the treatment of the rare heart disease ATTR-CM needs at least a 96% discount off its list price to be considered cost-effective under common benchmarks, a draft report by ICER has found.
Pharmaceutical Technology
JULY 18, 2024
The Phase III trial evaluating Nubeqa in patients with metastatic hormone-sensitive prostate cancer met its primary endpoint.
Fierce Pharma
JULY 18, 2024
As biopharma companies and the U.S. | As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JULY 18, 2024
The new hub will act as a central point of connection and engagement for the rare disease community for FDA-related concerns.
Fierce Pharma
JULY 18, 2024
Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade. | Even as argenx begins to chart a course toward a future beyond Vyvgart, the company’s flagship FcRn inhibitor still has plenty of tricks in store for the remainder of the decade.
Pharmaceutical Technology
JULY 18, 2024
The UK MHRA has approved Pierre Fabre’s vibegron for the treatment of overactive bladder (OAB) syndrome in adult patients.
BioPharma Reporter
JULY 18, 2024
CordenPharma, a US-based contract development and manufacturing organization (CDMO), will be making a â900 million investment over the next three years into expanding its peptide technology platform at its US and Europe sites.
Pharmaceutical Technology
JULY 18, 2024
CytoReason has secured $80m in funding from a consortium of investors to expand and enhance its AI disease models.
BioPharma Reporter
JULY 18, 2024
Contract development and manufacturing organizations (CDMOs) perform vital services for the biopharmaceutical industry â a role that is growing as cell and gene therapies gain momentum. Here are five of the top CDMOs bringing advanced therapies toward the market.
Pharmaceutical Technology
JULY 18, 2024
hVIVO specialises in human challenge trials for influenza and RSV therapeutic candidates.
Outsourcing Pharma
JULY 18, 2024
Japanese medical devices company, Nipro Medical Corporation, a giant in the healthcare and medical device industry, has announced a major investment of $397.8 million to establish its first North American manufacturing center of excellence in Greenville, North Carolina.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
JULY 18, 2024
J&J has three of its top-selling drugs in Medicare pricing negotiations but does not expect a major hit to its finances next year
BioPharma Reporter
JULY 18, 2024
Rocheâs recent $2.7 billion acquisition of Carmot Therapeutics is paying off, with positive results for new oral GLP-1 receptor agonist.
pharmaphorum
JULY 18, 2024
The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector's role in rising healthcare costs in the US.The hearing – scheduled for 23rd July – is part of an ongoing investigation by the committee into PBMs' alleged anticompetitive practices launched last year and spearheaded by chairman James Comer (R-Ky).
Fierce Pharma
JULY 18, 2024
In the year since the Humira biosimilar floodgates opened, AbbVie’s star immunology player has proven tough to drown out. | Through GoodRx, the German drugmaker's Humira copycat is priced 92% cheaper than AbbVie's branded Humira, which still holds 82% of the market despite the biosimilar competition.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharma Times
JULY 18, 2024
The most commonly diagnosed cancer in men in the UK leads to over 12,000 annual deaths
Fierce Pharma
JULY 18, 2024
The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death in kidney cancer patients who had tried an im | The addition of Bristol Myers Squibb’s Opdivo to a low dose of Aveo Oncology’s Fotivda failed to extend the time before tumor progression or death compared with Fotivda alone in kidney cancer patients who had tried an immune checkpoint inhibitor.
pharmaphorum
JULY 18, 2024
Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases
Drug Patent Watch
JULY 18, 2024
Transitioning to a new Contract Development and Manufacturing Organization (CDMO) can be a complex and challenging process.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioSpace
JULY 18, 2024
GRO Biosciences will use the Series B funds to launch a Phase I trial for ProGly-Uricase, its investigational therapy for gout.
Pharma Times
JULY 18, 2024
Genentech’s Pulmozyme could also treat other respiratory infections and conditions
Outsourcing Pharma
JULY 18, 2024
At the DIA 60th annual conference in San Diego, senior editor Liza Laws from Outsourcing Pharma had the opportunity to sit down with Marwan Fathallah, President and CEO of DIA.
Fierce Pharma
JULY 18, 2024
After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo | After storming the market with its longer-acting macular degeneration shot Vabysmo, Roche is laying the groundwork to expand the reach of its other eye disease innovation—refillable implant Susvimo.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
309 
Let's personalize your content